Several new 1-(4-diarylmethylpiperazine-1-yl)-2-(1H-indol-3-yl)ethane-1,2-dione derivatives were synthesized by acylation of 1-diarylmethylpiperazine with 2-(1H-indol-3-yl)-2-oxoacetyl chloride. Their structures were confirmed by 1 H NMR, IR, mass spectra, and elemental analysis. These compounds were further evaluated for their anticancer activity, and most of them were found to have moderate-to-potent antiproliferative activities against Hela, A-549, and ECA-109 cancer cell lines in vitro.
Introduction
Compounds containing the 1-(1H-indol-3-yl)ethane-1,2-dione have antiviral [1] , antimicrobial [2] , and anticancer [3] activities. For example, compound 1, named BMS-378806, has been found to have good HIV-1 attachment inhibitory activity in preventing entry to the host cell by binding to the viral envelope gp120 [1] ; compound 2, an indolylglyoxamide derivative, has good antibacterial activity against Grampositive pathogens [2] ; compound 3 exhibited good ATPbinding cassette (ABC) transporter modulatory activity and can be used as a potential anticancer agent [3] .
Until now, the N 4 -substituent of the piperazine ring of the above-reported compounds contains only an aryl group ( Figure 1 ) [4] [5] [6] , and there have been few reports on diarylsubstituted compounds. Herein, we adopted a skeleton splicing method to design a new class of compounds, 1-(1H-indol-3-yl)-2-(4-diarylmethylpiperazine-1-yl)ethane-1,2-dione derivatives, which not only contain the skeleton of 1-(piperazine-1-yl)-2-(1H-indol-3-yl)ethane-1,2-dione (from compounds 1 and 2) but also contain the skeleton of a diaryl methyl group (from compound 3).
Results and Discussion
The reactions for synthesis of 1-(1H-indol-3-yl)-2-(4-diarylmethylpiperazine-1-yl)ethane-1,2-dione derivatives (19-30) are summarised in Scheme 1. Compounds 4-6 were prepared from indole and oxalyl chloride in anhydrous ether at 0∼ 5 ∘ C under the protection of nitrogen [7] . Compounds 7-10 were obtained from diaryl ketones in the presence of sodium borohydride in methanol at reflux [8] . A following chlorination of 7-10 with a stoichiometric amount of thionyl chloride in dichloromethane at room temperature afforded 11-14 [9] . Compounds 11-14 were then treated with piperazine in DMF at 80 ∘ C to yield 15-18 [9] , acylation of which with 1 in the presence of triethylamine in dry THF, and then gave compounds 19-30 [10] .
In the infrared (IR) spectra of 19-30, the most characteristic absorptions are at 3154-3225 cm −1 (NH) and 1612-1652 cm −1 ((C=O) 2 broad peaks). In the 1 H NMR spectra, for compounds 19-30, characteristic signals due to the (NH) protons appeared at 12.22-12.46 ppm, and signals due to the (CH) protons attached to the diaryl moiety appeared at 4.37-4.43 ppm.
Compounds 19-30 were tested in vitro for anticancer activity by MTT assays against cervix uterus cancer cell Hela, human lung adenocarcinoma cell A-549, and human esophageal carcinoma cancer cell ECA-109. Cisplatin (DDP) was employed as a positive control in the assay. The results are presented in Table 1 .
According to 
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Experimental
Melting points were carried out on a XRC-1 apparatus and are uncorrected (Beijing Technical Instrument Co.). Infrared spectra were recorded, from KBr discs of solid materials, on a Nicolex FI-IR-170 instrument. The 1 H NMR spectra were run on a Bruker AC500 (500 MHz). Compounds were dissolved in d 6 -DMSO, and chemical shifts were referenced to TMS. Mass spectra were obtained on a Agilent 1260 lon Trap LC/MS 500 analysis system. Elemental analyses were performed on a Thermo-Finnigan Flash EA 1112 instrument. TCL was carried out on silica gel UV-254 plates.
Synthesis of Compounds (15-18).
Compounds 15-18 were synthesized from 7-10 via 11-14 according to literature methods [9] , respectively. Compounds 7-10 were obtained from diaryl ketones in the presence of sodium borohydride in methanol at reflux [8] . Compounds, 11 [11] , 12 [8] , 13 [12] , 14 [13] , 15 [11] , 16 [8] , and 17 [12] , were reported in literatures.
But the characterized data of compound 18 had not been reported. : General Procedure. Triethylamine was added to the mixture of 1-diarylmethylpiperazine compounds 15-18 (9.5 mmol) and compounds 4-6 (10 mmol) in THF (50 mL) with acyl chloride (10 mmol) at 0 ∘ C; the mixture was kept under magnetic stirring for 30 min and then was warmed up to room temperature for 10∼20 h at which time the progress of the reaction was monitored by thin-layer chromatography (ethyl acetate : alcohol = 9 : 1). The reaction mixture was then concentrated under reduced pressure and the residue was purified by column chromatography on silica gel (eluent: 2% EtOH in EtOAc) to obtain title compounds 19-30. Benzhydrylpiperazine-1-yl)-2-(5-bromo-1H-indol-3-yl) 
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Treatment of Tumor Cell Lines.
The antiproliferative activity of compounds 19-30 against several human cancer cell lines was assayed by standard MTT assay procedures. Cells were cultured in DMEM medium at 37 ∘ C with 5% CO 2 and 95% air, supplemented with 10% (V/V) bovine calf serum [14] . Cells were plated in 96-well plates at the density of 10,000 cells per well. After 24 h, the cells were treated with various concentrations of compounds from 1.0 to 100.0 g/mL. Wells containing culture medium without cells were used as blanks and cisplatin was assayed at the same time as a positive control. The cells were further incubated for 72 h. The cytotoxicity was measured by adding 5 mg/mL of MTT to each well and incubated for another 4 h. The formazan crystals were dissolved by adding 150 L of DMSO to each well. The optical density of each well was then measured on a microplate spectrophotometer at a wavelength of 570 nm. The IC 50 value ( g/mL) was determined from plots of % viability against dose of compound added.
The calculation formula of IC 50 values has been revised as follows:
where is the log value of the designed maximum concentration, is the log value of dilution ratio, and Σ is the sum of growth inhibition rate of each group:
where (%) is the growth inhibition rate, are the mean OD values for experimental groups, and are the mean OD values for control groups.
Conclusion
A series of indoleoxoacetic piperazine derivatives 19∼30 were synthesized and characterized. The in vitro antitumor activities of these compounds against Hela, A-549, and ECA-109 cells were evaluated. The effects of compounds 19-26 are all superior to DDP against all tested cancer cell lines, and compounds 20, 19, and 23 showed the best antiproliferative effect on Hela, A-549, and ECA-109 cells, respectively. These results encourage us to synthesize additional new indoleoxoacetic piperazine derivatives with the expected more potent antitumor activity.
